89,287 AstraZeneca Plc $AZN Shares Sold by Apollon Wealth Management LLC

Key Points

• Apollon Wealth Management cut its AstraZeneca stake by 91.8% in the third quarter, selling 89,287 shares and retaining 8,010 shares valued at approximately $1.29 million. Institutional investors collectively own 20.35% of the company.
• AstraZeneca reported a strong third quarter, with EPS of $2.79 beating the $2.60 consensus and revenue rising 6.5% year over year to $16.21 billion. Oncology sales increased 17%, helping offset generic competition affecting mature products such as Farxiga.
• The company reaffirmed its 2026 growth guidance and cited more than $20 billion in potential from drug-trial readouts expected in 2027. Analysts remain generally positive, with a “Moderate Buy” consensus and a $206.67 price target, though some firms maintain Hold ratings.

Apollon Wealth Management LLC reduced its holdings in shares of AstraZeneca Plc (NYSE:AZN - Free Report) by 91.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,010 shares of the company's stock after selling 89,287 shares during the quarter. Apollon Wealth Management LLC's holdings in AstraZeneca were worth $1,294,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of AZN. Aries Wealth Management boosted its stake in AstraZeneca by 1.3% in the third quarter. Aries Wealth Management now owns 4,546 shares of the company's stock valued at $741,000 after acquiring an additional 60 shares during the last quarter. Paladin Wealth LLC grew its holdings in AstraZeneca by 76.0% during the third quarter. Paladin Wealth LLC now owns 2,916 shares of the company's stock valued at $471,000 after purchasing an additional 1,259 shares during the period. Financial Management Professionals Inc. purchased a new stake in AstraZeneca in the third quarter worth $72,000. Signaturefd LLC increased its position in AstraZeneca by 3.3% in the third quarter. Signaturefd LLC now owns 36,720 shares of the company's stock worth $5,929,000 after buying an additional 1,184 shares during the last quarter. Finally, Brookmont Capital Management raised its stake in shares of AstraZeneca by 3.2% in the third quarter. Brookmont Capital Management now owns 27,272 shares of the company's stock valued at $4,404,000 after buying an additional 836 shares during the period. Hedge funds and other institutional investors own 20.35% of the company's stock.

Key Headlines Impacting AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: Core EPS reached $2.79 versus the roughly $2.60 analyst consensus, while revenue increased about 7% year over year to $16.21 billion, topping estimates near $16 billion. Net profit rose to $3.12 billion from $2.54 billion a year earlier. AstraZeneca Stock Rallies on Q3 Earnings Beat
• Positive Sentiment: Oncology remains the key growth engine: Cancer-drug sales rose 17%, helping offset generic competition and declining sales from mature medicines such as Farxiga. The performance suggests AstraZeneca’s newer products are mitigating patent-cliff pressure. AZN Q3 Earnings Beat Estimates
• Positive Sentiment: Pipeline catalysts support the longer-term story: Management highlighted more than $20 billion of potential from 2027 drug-trial readouts, while the company reported 12 positive Phase 3 readouts. These catalysts could expand AstraZeneca’s growth prospects beyond its current portfolio. AstraZeneca CEO Sees Over $20B Potential
• Positive Sentiment: Guidance was reaffirmed: AstraZeneca maintained its fiscal 2026 outlook for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. The company also targeted $1.5 billion in annual savings, potentially supporting margins and earnings. AstraZeneca Reports Q3 Revenue Growth
• Neutral Sentiment: Analyst views remain mixed: Guggenheim maintained a Buy rating, while Deutsche Bank retained Hold and Erste Group Bank lowered its FY2026 EPS estimate, indicating some valuation and execution concerns remain. Guggenheim Maintains Buy Rating
• Negative Sentiment: Generic competition remains a headwind: Farxiga and other mature products face pricing and volume pressure, which could limit growth if newer oncology and pipeline medicines do not continue to scale. AstraZeneca Holds Guidance

AstraZeneca Stock Up 6.9%

Shares of NYSE AZN opened at $186.49 on Friday. AstraZeneca Plc has a 52 week low of $153.41 and a 52 week high of $212.71. The business has a 50-day simple moving average of $164.48 and a two-hundred day simple moving average of $180.21. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The company has a market cap of $289.23 billion, a P/E ratio of 27.88, a P/E/G ratio of 1.35 and a beta of 0.27.

AstraZeneca (NYSE:AZN - Get Free Report) last posted its earnings results on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, beating analysts' consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.45% and a net margin of 17.02%. The business had revenue of $16.21 billion during the quarter, compared to analyst estimates of $16 billion. During the same quarter in the previous year, the firm earned $2.38 EPS. The company's quarterly revenue was up 6.5% compared to the same quarter last year. Research analysts anticipate that AstraZeneca Plc will post 10.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of research reports. Royal Bank Of Canada initiated coverage on AstraZeneca in a research note on Tuesday, September 8th. They issued an "outperform" rating on the stock. Citigroup reiterated a "buy" rating on shares of AstraZeneca in a research report on Tuesday, October 6th. Zacks Research upgraded shares of AstraZeneca from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 13th. CICC Research initiated coverage on shares of AstraZeneca in a research report on Sunday, August 23rd. They issued an "outperform" rating and a $198.00 price target on the stock. Finally, HSBC cut shares of AstraZeneca from a "buy" rating to a "hold" rating in a research note on Monday, July 13th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $206.67.

About AstraZeneca

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.